RxDoctor Payments DataLook up a doctor →

Siddharth Mathur, MD

Gastroenterology · Crystal River, FLNPI 1578728986

Payments from drug & device makers

$966,316in general payments, 2019–2025

Across 704 payments — averaging $1372.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$474K
  • Ironwood Pharmaceuticals, Inc$160K
  • Phathom Pharmaceuticals, Inc.$136K
  • AbbVie$125K
  • E.r. Squibb & Sons, L.L.C.$43K
  • AstraZeneca$20K
  • plus $9K from 32 others

What the payments were for

  • Consulting fees$220%
  • Speaking & faculty fees$76,11073%
  • Travel & lodging$14,44314%
  • Food & beverage$14,18514%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$966,316 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$416,251
Medicare patients
893
Services billed
3,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac387$66,627
LinzessLinaclotide51$55,586
VoqueznaVonoprazan Fumarate32$19,865
TrulancePlecanatide20$16,226
Mesalamine26$13,025
Omeprazole543$8,345
Colestipol Hcl41$3,588
Ursodiol18$3,011
Budesonide DrBudesonide21$2,823
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl110$1,984
Pantoprazole Sodium112$1,901
Famotidine106$1,853
Sucralfate65$1,200
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg44$1,100
Esomeprazole Magnesium15$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$379$66,627387 claims
AbbVieLinzess$124,988$55,58651 claims
Phathom Pharmaceuticals, Inc.Voquezna$135,807$19,86532 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$769$16,22620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Crystal River

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →